Association of L-tryptophan and an illness resembling eosinophilic fasciitis. Clinical and histopathologic findings in four patients with eosinophilia-myalgia syndrome.
The Centers for Disease Control has recently reported an association between the use of oral L-tryptophan preparations and a disease marked by severe myalgia, peripheral eosinophilia, and neuromuscular and cutaneous abnormalities. They have labeled the condition eosinophilia-myalgia syndrome. We report here the clinical and histopathologic findings in 4 patients who developed an illness resembling eosinophilic fasciitis following the initiation of oral L-tryptophan supplementation.
Bulpitt
K J
KJ
Department of Medicine, University of California, Los Angeles School of Medicine.
Verity
M A
MA
Clements
P J
PJ
Paulus
H E
HE
D000328:Adult; D001706:Biopsy; D004802:Eosinophilia / Q000139:chemically induced* / Q000473:pathology; D005208:Fasciitis / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced / Q000473:pathology; D012867:Skin / Q000473:pathology; D013577:Syndrome; D014364:Tryptophan / Q000009:adverse effects*
D014364:Tryptophan